sion of prices is a continuous process in which both decrease and increase take place. In the year 1990, the prices of more than 280 formulations have been revised down-ward. Cases of non-implementation of prices as and when brought to the notice of the Government are dealt with in accordance with the provisions of the Drug Price Control Order.

Recovery under DPEA

396. SHRI RAJNI RANJAN SAHU:
CHOWDHARY RAM SEWAK:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that huge amount is due for recovery under Drug Price Equalisation Account;

(b) if so, what is the estimated amount to be recovered; and

(c) what is the position of recovery in each case and what is the amount recovered during the current year?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Yes, Sir.

(b) and (c) A statement giving the details of tentative amounts due from each of the companies, amount so far deposited and the balance amount due is attached. During the current financial year an amount of Rs. 1.09 crores have been recovered so far.

Statement

Sl. No.	Name of the Company	Tentative amount calculated for the period 31-12-83 after review (Rs. in lakhs)	Amounts deposited so far (Rs. in lakhs)	Balance amount due (Rs. in lakhs)
(A)	*Supreme Court Case :*			
1.	M/s. Cyanamid India Ltd.	536·91	100·00	436·91
2.	M/s. Hoechst India Ltd.	2491·05	312·10	2178·95
3.	M/s. John Wyeth India Ltd. & M/s. Geoffery Manners Ltd.	177·67 28·37	45·00	161·04
4.	M/s. Ethnor Limited	10·19	10·19	—
5.	M/s. Franco Indian Pharmaceuticals Ltd. and M/s. Griffon Limited	14·02	0·43	13·59
6.	M/s. Pfizer Limited	87·61	19·90	67·71
7.	M/s. Anil Starch Products Ltd.	11·61	Nil	11·61
8.	M/s. S.G. Pharmaceuticals	205·36	Nil	205·36
9.	M/s. Tamilnadu Dadha Pharmaceuticals	37·97	Nil	37·97
10.	M/s. Merind Limited	781·58	Nil	781·58
		4382·34	487·62	3894·72

(B) *Details of tentative amounts assured and recoverable under Para 7 (2) of DPCO, 1979.*

Sl. No.	Name of the Company	Period involved	Tentative amount assessed (Rs. in lakhs)	Amount Deposited so far (Rs. in lakhs)	Balance amount due (Rs. in lakhs)
1	2	3	4	5	6
	RIFAMPICIN				
1.	Blochem Pharmaceuticals	3/79 to 3/84	34·28	..	34·28
2.	M/s. Lyka Labs.	4/79 to 3/84	57·57	5·70	51·87
3.	Astra IDL Ltd.	82/83 to 5/84	24·11	2·41	21·70
4.	Micro Labs.	79-80 to 82/83	2·24	..	2·24
5.	Themis Chemicals Limited	82/83 to 83/84	36·31	..	36·31
6.	Alembic Chem. Labs.	81-82 to 83-84	38·73	3·80	34·93
7.	Bombay Drug House	80-81 to 83-84	1·73	..	1·73
8.	Pharmed Pvt. Ltd.	79-80 to 83-84	66·01	..	66·01
9.	Dalphin Labs.	1979 to 1983	18·11	..	18·11
10.	Albert David Ltd.	11/81 to 9/83	3·91	3·91	Nil
11.	Pharma & Chem. Ind.	80-81 to 82-83	87·99	..	87·99
12.	Cadila Labs. P. Ltd.	79-80 to 83-84	76·52	7·50	69·02
13.	Sarabhai Chemicals	82-83 to 83/84	4·14	2·00	2·14
14.	Lupin Labs.	8/80 to 3/84	215·89	21·60	194·29
15.	Ranbaxy Labs.	4/79 to 6/84	36.23	3·63	32·60
16.	Wallace Pharmaceuticals	4/82 to 2/84	2·82	0·29	2·53
17.	Ethico Drug & Chem. Mfdg.	5/82 to 3/84	140.98	..	140·98
18.	Indian Drugs Pharmaceuticals Ltd.	12/80 to 1/86	2·18	..	2·18
19.	Hindustan Antibiotics Limited	81-82 to 83-84	36·66	..	36·66
			886·41	50.84	835·57
	DIPYRIDAMO				
1.	Glenmark Remedies	4/79 to 7/84	59·95	59·95	Nil
	GENTAMYCIN				
1.	Fulford I. Ltd.	79-80 to 2/84	194·62	50·00	144·62
2.	Biochem Pharma Ltd.	79-80 to 3/84	33·88	..	33·88

1	2	3	4	5	6
3.	Lyka Labs Ltd.	7/ 9 to 3/84	17·47	1·75	15·72
4.	Nicholas Labs.	79-80 to 3/84	53·03	10·00	43·03
			299·00	61·75	237·25
	SALBUTAMOL				
1.	Khandelwal Ltd.	79-80 to 81-82	0·15	..	0·15
2.	Biddle Sawyer P. Ltd.	4/79 to 3/83	142·74	..	142·74
			142·89	..	142·89
	CLOFAZAMINE				
1.	B.G. Pharmaceuticals	4/79 to 3/84	5·01	..	5·01
	AMPICILIN AND AMOXICILLIN				
1.	Brochem Pharma Ltd.	79-80 to 83-84	11·80	..	11·80
	OXYPHENYBUTAZONE				
1.	Tablets India Ltd.	79-80 to 83-84	9·49	..	9·49
	METRONIDAZOLE				
1.	Boots Co. Ltd.	79-80 to 25-8-87	62·17	47·91	14·26
2.	Smith Stanistreet Pharmaceuticals Ltd.	79-80 to 83-84	7·82	..	7·82
3.	KSPDL	79-80 to 83-84	5·5	..	5·50
4.	Khandelwal Labs.	79-80 to 83-84	1·34	..	1·34
5.	M/s. IDPL	79-80 to 83-84	20·33	..	20·33
			97·16	47·91	49·25
	SULPHAMETHOXAZOLE				
1.	M/s. Burroughs Welcome	79-80 to Feb. 84	441·27	..	441·27
	TRIMETHOPRIM				
1.	M/s. German Remedies	2/82 to 5/86	8·25	8·25	Nil
	FLUCINOLONE ACETONIDE				
1.	M/s. Lyka Labs.	79-80 to 25-8-87	678·73	..	678·73

1	2	3	4	5	6
(C) *Amounts recovered in High Court cases.*					
1.	Sarabhai M. Chemicals. . .	N.A.	..	20·00	..
2.	Glaxo		6635·00	819·00	5816·00
(D) *Amounts due against overcharging :*					
1.	M/s. Warner Hindustan Ltd. now Parke Davis		106·36	55·49	50·87
2.	M/s. Boehringar Kholi Ltd.		97·74	..	97·74
3.	M/s. IDPL		336·45	Nil	386·45
4.	M/s. A.P. Chemicals . . .		25·43	Nil	25·43
5.	M/s. Malladi Drugs . . .		116·30	Nil	116·30
6.	M/s. IDPL (Sulphadimidine) .		37·30	Nil	37·30
7.	M/s. Krupa Traders		20·48	Nil	20·48
			740·06	55·49	684·57

Review of the recommendations of Kelkar Committee

397. CHOWDHARY RAM SEWAK: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry have appointed a Standing Committee to review the recommendations of Kelkar Committee;

(b) if so, what are the details of recommendations reviewed by the Committee upto 15th December, 1990; and

(c) what are the details of review in each case and how many of these findings have been implemented?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Yes, Sir.

(b) and (c) The recommendations made by the Standing Committee with regard to major|minor ingredients, categorisation of combination formulations etc. have been implemented. The other issues are before the Standing Committee and it is not in public interest to reveal the details of the recommendations made by this committee, till such time a final decision on various issues is taken by the Government.

Recovery of DPEA dues

398. SHRI BEKAL UTSAHI:
CHOWDHARY RAM SEWAK:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry have referred certain cases to Collectors for recovery of amount under DPEA;

(b) if so, what are the details thereof;

(c) what is the provision of law under which such cases were referred; and

(d) what are the details of cases where recovery has not been made and what are the cases which are being referred to Collectors for recovery as Land Revenue